These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 37989731)

  • 1. Antibody-directed evolution reveals a mechanism for enhanced neutralization at the HIV-1 fusion peptide site.
    Banach BB; Pletnev S; Olia AS; Xu K; Zhang B; Rawi R; Bylund T; Doria-Rose NA; Nguyen TD; Fahad AS; Lee M; Lin BC; Liu T; Louder MK; Madan B; McKee K; O'Dell S; Sastry M; Schön A; Bui N; Shen CH; Wolfe JR; Chuang GY; Mascola JR; Kwong PD; DeKosky BJ
    Nat Commun; 2023 Nov; 14(1):7593. PubMed ID: 37989731
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of a 3Mut-Apex-Stabilized Envelope Trimer That Expands HIV-1 Neutralization Breadth When Used To Boost Fusion Peptide-Directed Vaccine-Elicited Responses.
    Chuang GY; Lai YT; Boyington JC; Cheng C; Geng H; Narpala S; Rawi R; Schmidt SD; Tsybovsky Y; Verardi R; Xu K; Yang Y; Zhang B; Chambers M; Changela A; Corrigan AR; Kong R; Olia AS; Ou L; Sarfo EK; Wang S; Wu W; Doria-Rose NA; McDermott AB; Mascola JR; Kwong PD
    J Virol; 2020 Jun; 94(13):. PubMed ID: 32295908
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mutational fitness landscapes reveal genetic and structural improvement pathways for a vaccine-elicited HIV-1 broadly neutralizing antibody.
    Madan B; Zhang B; Xu K; Chao CW; O'Dell S; Wolfe JR; Chuang GY; Fahad AS; Geng H; Kong R; Louder MK; Nguyen TD; Rawi R; Schön A; Sheng Z; Nimrania R; Wang Y; Zhou T; Lin BC; Doria-Rose NA; Shapiro L; Kwong PD; DeKosky BJ
    Proc Natl Acad Sci U S A; 2021 Mar; 118(10):. PubMed ID: 33649208
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Consistent elicitation of cross-clade HIV-neutralizing responses achieved in guinea pigs after fusion peptide priming by repetitive envelope trimer boosting.
    Cheng C; Xu K; Kong R; Chuang GY; Corrigan AR; Geng H; Hill KR; Jafari AJ; O'Dell S; Ou L; Rawi R; Rowshan AP; Sarfo EK; Sastry M; Saunders KO; Schmidt SD; Wang S; Wu W; Zhang B; Doria-Rose NA; Haynes BF; Scorpio DG; Shapiro L; Mascola JR; Kwong PD
    PLoS One; 2019; 14(4):e0215163. PubMed ID: 30995238
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diverse Murine Vaccinations Reveal Distinct Antibody Classes to Target Fusion Peptide and Variation in Peptide Length to Improve HIV Neutralization.
    Sastry M; Changela A; Gorman J; Xu K; Chuang GY; Shen CH; Cheng C; Geng H; O'Dell S; Ou L; Rawi R; Reveiz M; Stewart-Jones GBE; Wang S; Zhang B; Zhou T; Biju A; Chambers M; Chen X; Corrigan AR; Lin BC; Louder MK; McKee K; Nazzari AF; Olia AS; Parchment DK; Sarfo EK; Stephens T; Stuckey J; Tsybovsky Y; Verardi R; Wang Y; Zheng CY; Chen Y; Doria-Rose NA; McDermott AB; Mascola JR; Kwong PD
    J Virol; 2023 May; 97(5):e0160422. PubMed ID: 37098956
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neutralizing Activity of Broadly Neutralizing Anti-HIV-1 Antibodies against Clade B Clinical Isolates Produced in Peripheral Blood Mononuclear Cells.
    Cohen YZ; Lorenzi JCC; Seaman MS; Nogueira L; Schoofs T; Krassnig L; Butler A; Millard K; Fitzsimons T; Daniell X; Dizon JP; Shimeliovich I; Montefiori DC; Caskey M; Nussenzweig MC
    J Virol; 2018 Mar; 92(5):. PubMed ID: 29237833
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Complete functional mapping of infection- and vaccine-elicited antibodies against the fusion peptide of HIV.
    Dingens AS; Acharya P; Haddox HK; Rawi R; Xu K; Chuang GY; Wei H; Zhang B; Mascola JR; Carragher B; Potter CS; Overbaugh J; Kwong PD; Bloom JD
    PLoS Pathog; 2018 Jul; 14(7):e1007159. PubMed ID: 29975771
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Panels of HIV-1 Subtype C Env Reference Strains for Standardized Neutralization Assessments.
    Hraber P; Rademeyer C; Williamson C; Seaman MS; Gottardo R; Tang H; Greene K; Gao H; LaBranche C; Mascola JR; Morris L; Montefiori DC; Korber B
    J Virol; 2017 Oct; 91(19):. PubMed ID: 28747500
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antibody Lineages with Vaccine-Induced Antigen-Binding Hotspots Develop Broad HIV Neutralization.
    Kong R; Duan H; Sheng Z; Xu K; Acharya P; Chen X; Cheng C; Dingens AS; Gorman J; Sastry M; Shen CH; Zhang B; Zhou T; Chuang GY; Chao CW; Gu Y; Jafari AJ; Louder MK; O'Dell S; Rowshan AP; Viox EG; Wang Y; Choi CW; Corcoran MM; Corrigan AR; Dandey VP; Eng ET; Geng H; Foulds KE; Guo Y; Kwon YD; Lin B; Liu K; Mason RD; Nason MC; Ohr TY; Ou L; Rawi R; Sarfo EK; Schön A; Todd JP; Wang S; Wei H; Wu W; ; Mullikin JC; Bailer RT; Doria-Rose NA; Karlsson Hedestam GB; Scorpio DG; Overbaugh J; Bloom JD; Carragher B; Potter CS; Shapiro L; Kwong PD; Mascola JR
    Cell; 2019 Jul; 178(3):567-584.e19. PubMed ID: 31348886
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-V3/Glycan and Anti-MPER Neutralizing Antibodies, but Not Anti-V2/Glycan Site Antibodies, Are Strongly Associated with Greater Anti-HIV-1 Neutralization Breadth and Potency.
    Jacob RA; Moyo T; Schomaker M; Abrahams F; Grau Pujol B; Dorfman JR
    J Virol; 2015 May; 89(10):5264-75. PubMed ID: 25673728
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Global panel of HIV-1 Env reference strains for standardized assessments of vaccine-elicited neutralizing antibodies.
    deCamp A; Hraber P; Bailer RT; Seaman MS; Ochsenbauer C; Kappes J; Gottardo R; Edlefsen P; Self S; Tang H; Greene K; Gao H; Daniell X; Sarzotti-Kelsoe M; Gorny MK; Zolla-Pazner S; LaBranche CC; Mascola JR; Korber BT; Montefiori DC
    J Virol; 2014 Mar; 88(5):2489-507. PubMed ID: 24352443
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Subtle Longitudinal Alterations in Env Sequence Potentiate Differences in Sensitivity to Broadly Neutralizing Antibodies following Acute HIV-1 Subtype C Infection.
    Mandizvo T; Gumede N; Ndlovu B; Ndlovu S; Mann JK; Chopera DR; Singh L; Dong KL; Walker BD; Ndhlovu ZM; Lavine CL; Seaman MS; Gounder K; Ndung'u T
    J Virol; 2022 Dec; 96(24):e0127022. PubMed ID: 36453881
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Envelope variants circulating as initial neutralization breadth developed in two HIV-infected subjects stimulate multiclade neutralizing antibodies in rabbits.
    Malherbe DC; Pissani F; Sather DN; Guo B; Pandey S; Sutton WF; Stuart AB; Robins H; Park B; Krebs SJ; Schuman JT; Kalams S; Hessell AJ; Haigwood NL
    J Virol; 2014 Nov; 88(22):12949-67. PubMed ID: 25210191
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Induction of a Tier-1-Like Phenotype in Diverse Tier-2 Isolates by Agents That Guide HIV-1 Env to Perturbation-Sensitive, Nonnative States.
    Johnson J; Zhai Y; Salimi H; Espy N; Eichelberger N; DeLeon O; O'Malley Y; Courter J; Smith AB; Madani N; Sodroski J; Haim H
    J Virol; 2017 Aug; 91(15):. PubMed ID: 28490588
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Limited Evidence for a Relationship between HIV-1 Glycan Shield Features in Early Infection and the Development of Neutralization Breadth.
    Li Y; Bai H; Sanders-Buell E; Dussupt V; Townsley S; Donofrio G; Bose M; O'Sullivan AM; Kibuuka H; Maganga L; Nitayaphan S; Kosgei J; Pitisuttithum P; Rerks-Ngarm S; Eller LA; Michael NL; Robb ML; Ake J; Vasan S; Tovanabutra S; Krebs SJ; Rolland M
    J Virol; 2021 Aug; 95(17):e0079721. PubMed ID: 34160251
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clade C HIV-1 Envelope Vaccination Regimens Differ in Their Ability To Elicit Antibodies with Moderate Neutralization Breadth against Genetically Diverse Tier 2 HIV-1 Envelope Variants.
    Burton S; Spicer LM; Charles TP; Gangadhara S; Reddy PBJ; Styles TM; Velu V; Kasturi SP; Legere T; Hunter E; Pulendran B; Amara R; Hraber P; Derdeyn CA
    J Virol; 2019 Apr; 93(7):. PubMed ID: 30651354
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antibodies targeting the fusion peptide on the HIV envelope provide protection to rhesus macaques against mucosal SHIV challenge.
    Pegu A; Lovelace SE; DeMouth ME; Cully MD; Morris DJ; Li Y; Wang K; Schmidt SD; Choe M; Liu C; Chen X; Viox E; Rowshan A; Taft JD; Zhang B; Xu K; Duan H; Ou L; Todd JP; Kong R; Li H; Shaw GM; Doria-Rose NA; Kwong PD; Koup RA; Mascola JR
    Sci Transl Med; 2024 Jan; 16(730):eadh9039. PubMed ID: 38232141
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sensitivity to Broadly Neutralizing Antibodies of Recently Transmitted HIV-1 Clade CRF02_AG Viruses with a Focus on Evolution over Time.
    Stefic K; Bouvin-Pley M; Essat A; Visdeloup C; Moreau A; Goujard C; Chaix ML; Braibant M; Meyer L; Barin F
    J Virol; 2019 Jan; 93(2):. PubMed ID: 30404804
    [TBL] [Abstract][Full Text] [Related]  

  • 19. VRC34-Antibody Lineage Development Reveals How a Required Rare Mutation Shapes the Maturation of a Broad HIV-Neutralizing Lineage.
    Shen CH; DeKosky BJ; Guo Y; Xu K; Gu Y; Kilam D; Ko SH; Kong R; Liu K; Louder MK; Ou L; Zhang B; Chao CW; Corcoran MM; Feng E; Huang J; Normandin E; O'Dell S; Ransier A; Rawi R; Sastry M; Schmidt SD; Wang S; Wang Y; Chuang GY; Doria-Rose NA; Lin B; Zhou T; Boritz EA; Connors M; Douek DC; Karlsson Hedestam GB; Sheng Z; Shapiro L; Mascola JR; Kwong PD
    Cell Host Microbe; 2020 Apr; 27(4):531-543.e6. PubMed ID: 32130953
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased breadth of HIV-1 neutralization achieved by diverse antibody clones each with limited neutralization breadth.
    Chukwuma VU; Kose N; Sather DN; Sapparapu G; Falk R; King H; Singh V; Lampley R; Malherbe DC; Ditto NT; Sullivan JT; Barnes T; Doranz BJ; Labranche CC; Montefiori DC; Kalams SA; Haigwood NL; Crowe JE
    PLoS One; 2018; 13(12):e0209437. PubMed ID: 30566528
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.